- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04607096
Intermittent Fasting to Improve Insulin Secretion (IFIS)
Type 2 diabetes (T2D) mellitus is a challenge for health care systems as the numbers increases constantly. In 2014, 422 million people had been living with diabetes worldwide. The absolute numbers of people with prediabetes have also grown substantially over 25 years worldwide. In Germany, about 10% of the population has T2D and another 21 % of the population has prediabetes.Overall, 16% of all deaths in Germany are attributable to type 2 diabetes. Macro- and microvascular complications of diabetes imply a significant threat for the patients and are already present in the prediabetic state. Short term and long term complications, the burden of treatment, and reduced quality of life are major burdens of the disease. Accumulating data indicate that currently recommended therapeutic diet regimens in patients with obesity and diabetes are not sustainable on the long term. Novel concepts are therefore urgently needed.
T2D occurs when insulin secretion from pancreatic beta-cells cannot sufficiently be increased to compensate for insulin resistance. Causes of beta-cell dysfunction are heterogeneous. In addition, the most important determinants of diabetes remission are the extend of weight loss and restoration of beta-cell function. In the course of diabetes progression, the inability to recover insulin secretion might identify the state of no return to normal glucose tolerance. It is therefore crucial to improve insulin secretion in treatment and prevention of diabetes. Up to now lifestyle intervention trials in prediabetes or pharmacological intervention trials in diabetes did not show improvement of insulin secretion after intervention. However, one recent small human trial shows that intermittent fasting (early time restricted fasting) is able to improve insulin secretion.Currently, there are no trials that examine the effect of intermittent fasting in individuals with a broad range of impaired glucose metabolism (from prediabetes to diabetes). Recently novel subtypes of diabetes and prediabetes with high risk for the early manifestation of diabetes complications have been identified. Currently, prevention strategies for this high risk individuals have not been examined yet. We will study for the first time the effectiveness of 4 weeks intermittent fasting on changes in insulin secretion capacity in subphenotypes of diabetes and in prediabetes.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Andreas Fritsche, MD
- Phone Number: +49 7071 29 80590
- Email: andreas.fritsche@med.uni-tuebingen.de
Study Contact Backup
- Name: Michael Roden, MD
- Phone Number: +49 211 3382 201
- Email: michael.roden@ddz.de
Study Locations
-
-
-
Berlin, Germany, 10117
- Not yet recruiting
- Charité Berlin - Department of Endocrinology and Metabolic Diseases
-
Contact:
- Joachim Spranger, MD
- Phone Number: +49 30 450 514 252
- Email: joachim.spranger@charite.de
-
Dresden, Germany, 01307
- Not yet recruiting
- Universtiy Hospital Carl Gustav Carus
-
Contact:
- Peter Schwarz, MD
- Phone Number: +49 (0) 351 458271
- Email: peter.schwarz@uniklinikum-dresden.de
-
Duesseldorf, Germany, 40225
- Not yet recruiting
- German Diabetes Center
-
Contact:
- Michael Roden, MD
- Phone Number: +49 211 3382 201
- Email: michael.roden@ddz.de
-
Heidelberg, Germany, 69120
- Not yet recruiting
- Heidelberg University Hospital - Department of Endocrinology and Metabolism
-
Contact:
- Julia Szendrödi, MD
- Phone Number: +49 (0) 6221 56-8601
- Email: Julia.Szendrödi@med.uni-heidelberg.de
-
Leipzig, Germany, 04103
- Not yet recruiting
- University Hospital Leipzig - Clinic for Endocrinology and Nephrology
-
Contact:
- Matthias Blüher, MD
- Phone Number: +49 (0)341 - 97 13320
- Email: Matthias.blüher@medizin.uni-leipzig.de
-
Luebeck, Germany, 23538
- Not yet recruiting
- University of Luebeck - Institute of Endocrinology and Diabetes
-
Contact:
- Sebastian Schmid, MD
- Email: Sebastian.Schmid@uni-luebeck.de
-
Munich, Germany, 80992
- Not yet recruiting
- Technical University of Munich - Else Kroener-Fresenius-Center for Nutritional Medicine
-
Contact:
- Hans Hauner, MD
- Phone Number: +49 (0) 8928924911
- Email: hans.hauner@tum.de
-
Tuebingen, Germany, 72076
- Recruiting
- University Hospital Tuebingen - Institute for Diabetes Research and Metabolic Diseases (IDM)
-
Contact:
- Andreas Fritsche, MD
- Phone Number: +49 7071 29 80590
- Email: andreas.fritsche@med.uni-tuebingen.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Body mass index (BMI) between 25 - 40 kg/m²
- Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures.
- Subjects with prediabetes (IFG and/or IGT, HbA1c 5,4 % - 6,4 %, subphenotype cluster 3 or 5) or
- Subjects with diabetes mellitus type 2 (diagnosis < 1 year, HbA1c = 6,5 - 9 %, no medical treatment, subphenotype SIDD or SIRD)
Exclusion Criteria:
- Subjects with diabetes mellitus type 1 (GAD-, IA2-AB positive)
- Women during pregnancy and lactation
- Treamtent with any medication effecting on glucose metabolism like anti-diabetic drugs or steroids
- Subjects with a haemoglobin (Hb) ≤ 11.5 g/dl (for males) and Hb ≤ 10.5 g/dl (for females) at screening
- Any pancreatic disease
- Medical history of cancer and/or treatment for cancer within the last 5 years.
- Known current presence or history of severe neurological or psychiatric diseases, schizophrenia, bipolar disorder
- Known history of bariatric surgery
- Severe liver or kidney diseases (Alanine Aminotransferase (ALT [SGPT]), Aspartate Aminotransferase (AST [SGOT]) above 3 x upper limit of normal (ULN) or Glomerular Filtration Rate (eGFR) ≤ 60 ml/min (MDRD formula)
- Systemic infection (CRP > 1 mg/dl)
- Severe diabetic complications like chronic kidney disease (CKD), proliferating retinopathy or symptomatic cardiovascular disease
- Presence of any contraindication for the conduct of an MRI investigation, such as cardiac pacemakers, ferromagnetic haemostatic clips in the central nervous system, metallic splinters in the eye, ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators, cochlear implants, insulin pumps and nerve stimulators, prosthetic heart valves etc.
- Persons with limited temperature sensation and / or elevated sensitivity to warming of the body
- Persons with a hearing disorder or a increased sensitivity for loud noises
- Claustrophobia
- Participation in other clinical trials or observation period of competing trials up to 30 days prior to this study
- Refusal to get informed of unexpected detected pathological findings
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Prediabetic subjects - cluster 3
Presence of a cluster 3 phenotype will be examined according to the parameters described by Wagner et al.(Nat.
Med.
2020).
|
The intermittent fasting intervention consists of a decreased daily caloric intake of 400 kcal below individual requirements (Harris Benedict Formula) combined with early time restricted fasting according to the schema 16:8.
fasting will be performed over 4 weeks.
Control group will be advised to reduce daily caloric intake of 400 kcal below individual requirements (Harris Benedict formula)
|
Active Comparator: Prediabetic subjects - cluster 5
Presence of a cluster 5 phenotype will be examined according to the parameters described by Wagner et al.(Nat.
Med.
2020).
|
The intermittent fasting intervention consists of a decreased daily caloric intake of 400 kcal below individual requirements (Harris Benedict Formula) combined with early time restricted fasting according to the schema 16:8.
fasting will be performed over 4 weeks.
Control group will be advised to reduce daily caloric intake of 400 kcal below individual requirements (Harris Benedict formula)
|
Active Comparator: Patients with type 2 diabetes - subphenotype: Severe insulin-deficient diabetes (SIDD)
Presence of a SIDD phenotype will be examined according to the parameters de-scribed Ahlqvist et al. (Lancet Diabetes Endocrinol.
2018 May;6(5):361-369).
|
The intermittent fasting intervention consists of a decreased daily caloric intake of 400 kcal below individual requirements (Harris Benedict Formula) combined with early time restricted fasting according to the schema 16:8.
fasting will be performed over 4 weeks.
Control group will be advised to reduce daily caloric intake of 400 kcal below individual requirements (Harris Benedict formula)
|
Active Comparator: Patients with type 2 diabetes - subphenotype: Severe insulin-resistant diabetes (SIRD)
Presence of a SIRD phenotype will be examined according to the parameters de-scribed Ahlqvist et al (Lancet Diabetes Endocrinol.
2018 May;6(5):361-369).
|
The intermittent fasting intervention consists of a decreased daily caloric intake of 400 kcal below individual requirements (Harris Benedict Formula) combined with early time restricted fasting according to the schema 16:8.
fasting will be performed over 4 weeks.
Control group will be advised to reduce daily caloric intake of 400 kcal below individual requirements (Harris Benedict formula)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in first phase insulin secretion.
Time Frame: Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Effect of intermittent fasting vs. a control diet on glucose stimulated first phase insulin secretion adjusted for insulin sensitivity during an hyperglycemic clamp.
|
Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in second phase insulin secretion.
Time Frame: Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Effect of intermittent fasting vs. a control diet on glucose stimulated second phase insulin secretion adjusted for insulin sensitivity during an hyperglycemic clamp.
|
Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Change in insulin sensitivity.
Time Frame: Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Effect of intermittent fasting vs. a control diet on insulin sensitivity using insulin sensitivity index during an hyperglycemic clamp.
|
Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Change in BMI.
Time Frame: Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Effect of intermittent vs. a control diet fasting on BMI.
|
Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Change in liver fat content.
Time Frame: Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Effects of intermittent fasting vs. a control diet on liver fat content (%) measured by magnetic resonance spectroscopy (3 T whole body imaging).
|
Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Change in pancreatic fat content.
Time Frame: Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Effects of intermittent fasting on pancreatic fat content (%) measured by magnetic resonance spectroscopy (3 T whole body imaging).
|
Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Change in body fat content.
Time Frame: Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Effects of intermittent fasting vs. a control diet on total adipose tissue (TAT) measured by magnetic resonance tomography (3 T whole body imaging).
|
Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Change in visceral adipose tissue.
Time Frame: Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Effects of intermittent fasting vs. a control diet on visceral adipose tissue (VAT) measured by by magnetic resonance tomography (3 T whole body imaging)
|
Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Change in subcutaneous adipose tissue.
Time Frame: Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Effects of intermittent fasting vs. a control diet on subcutaneous adipose tissue (SCAT) measured by by magnetic resonance tomography (3 T whole body imaging)
|
Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in brain insulin sensitivity.
Time Frame: Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Effects of intermittent fasting vs. a control diet on brain insulin sensitivity measured by functional magnetic resonance imaging (fMRI) combined with nasal insulin administration.
|
Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Change in resting energy expenditure (REE).
Time Frame: Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Effects of intermittent fasting vs. a control diet on resting energy expenditure measured by indirect calorimetry.
|
Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Change in substrate oxidation.
Time Frame: Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Effects of intermittent fasting vs. a control diet on substrate oxidation measured by indirect calorimetry.
|
Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Change in proinsulin processing.
Time Frame: Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Effect of intermittent fasting vs. a control diet on first phase proinsulin processing during an hyperglycemic clamp.
|
Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Change in glucagon suppression.
Time Frame: Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Effect of intermittent fasting vs. a control diet on glucagon suppression during an hyperglycemic clamp.
|
Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Change in insuin clearance.
Time Frame: Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Effect of intermittent fasting vs. a control diet on insulin clearance during an hyperglycemic clamp.
|
Before, after 4 weeks and after 24 weeks of lifestyle intervention.
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 596/2020BO1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes type2
-
Mathias Ried-LarsenCompletedDiabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus | Type2 Diabetes | Type2 Diabetes MellitusDenmark
-
Johns Hopkins UniversityBeth Israel Deaconess Medical CenterActive, not recruitingHypertension | Diabetes Mellitus, Type 2 | Diabetes | Diabetes type2 | Type 2 Diabetes | Type2 Diabetes | Type II Diabetes | High Blood PressureUnited States
-
Sigrid Therapeutics ABCompletedOverweight | PreDiabetes | Prediabetic State | Type2 Diabetes | Obese | Type2 Diabetes Mellitus | Pre DiabetesFinland, Sweden
-
University of ChicagoCompleted
-
Michigan State UniversityUniversity of Michigan; Claremont Graduate UniversityUnknown
-
University of AlbertaSherwood Park Strathcona County Primary Care Network, AlbertaCompleted
-
Region SkaneGöteborg UniversityActive, not recruitingType2 DiabetesSweden
-
University of Missouri-ColumbiaCompleted
-
University Hospital, Gentofte, CopenhagenCompletedType2 DiabetesDenmark
Clinical Trials on Intermittent fasting
-
H. Lee Moffitt Cancer Center and Research InstituteNot yet recruitingPancreatitis | Pancreatitis, Chronic | Pancreatitis, Acute | Pancreas Disease | Acute Recurrent PancreatitisUnited States
-
Mahidol UniversityHealth Systems Research InstituteEnrolling by invitationWeight Loss | Obese | Intermittent Fasting | Behavioral Economic | HOMA-IRThailand
-
Ohio State UniversityNational Psoriasis FoundationRecruitingPsoriasis | Psoriatic ArthritisUnited States
-
Menoufia UniversityRecruitingLocally Advanced Breast Cancer | Intermittent FastingEgypt
-
University of CalgaryCrohn's and Colitis FoundationNot yet recruiting
-
Washington University School of MedicineCompletedRelapsing Remitting Multiple SclerosisUnited States
-
Charite University, Berlin, GermanyWestfälische Wilhelms-Universität MünsterCompleted
-
Istanbul Training and Research HospitalCompleted
-
Ministry of Health, MalaysiaCompletedObesity | Intermittent FastingMalaysia
-
gino gaddiniTerminatedPre-diabetes | Diabetes Type 2United States